Perez FA, Suárez CI, Zazo ERM, González MJ, Batista PM

Language: Spanish
References: 23
Page: 1-14
PDF size: 1387.86 Kb.

ABSTRACT

Dry eye is a common condition that has a significant impact on quality of life, leading to a feeling of discomfort and visual impairment. Additionally, it can have a pernicious effect on ocular surgical procedures, compromising the outcome of corneal, cataract and refractive surgeries. This lacrimal dysfunction syndrome is a multifactorial condition, derived from a deficiency or excessive tear evaporation. A search of the scientific literature was carried out with the aim of describing dry eye disease in a general way, providing updated information regarding its concept, epidemiology, classification, risk factors, pathophysiology, symptoms and signs, diagnostic challenges considering the complexity of the condition and its treatment. Early identification of subtypes and control of severity is crucial to improve patient welfare. The economic burden on society, and the impact of the disease on the individual, through its effect on vision, quality of life and work productivity, as well as on the psychological and physical aspects, are considerable. Therefore, it is important that ophthalmologists with the support of optometrists and ophthalmic technologists diagnose and treat the disease in its early stages, when signs and symptoms are not yet severe, which will slow down its natural progression, and possibly reduce the resulting harmful consequences.

REFERENCES

1. Willcox MD, Argüeso P, Georgiev GA, Holopatien JM, Laurie GW, Millar TJ, et al. TFOS DEWS II Tear Film Report. Ocul Surf. 2017;15(3):366-403. DOI: 10.1016/j.jtos.2017.03.0061.

2. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438-510. DOI: 10.1016/j.jtos.2017.05.0112.

3. Javadi MA, Feizi S. Dry eye syndrome. J Ophthalmic Vis Res. 2011 [acceso 26/05/2021];6(3):192-8. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/22454735/ 3.

4. Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. TFOS DEWS II Report Executive Summary. The Ocular Surface. 2017;15(4):802-12. DOI: 10.1016/j.jtos.2017.08.0034.

5. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua H, Liu ZS, et al. TFOS DEWS II Definition and Classification Report. The Ocular Surface. 2017;15(3):276-83. DOI: 10.1016/j.jtos.2017.05.0085.

6. Thulasi P, Djalilian A. Update in current diagnostics and therapeutics of dry eye disease. Ophthalmology. 2017;124(11):27-33. DOI: 10.1016/j.ophtha.2017.07.0226.

7. Golebiowski B, Badarudin N, Eden J, You J, Hampel U, Stapleton F. Does endogenous serum oestrogen play a role in meibomian gland dysfunction in postmenopausal women with dry eye?. Br J Ophthalmol. 2017;101(2):218-22. DOI: 10.1136/bjophthalmol-2016-3084737.

8. Sullivan DA, Rocha EM, Aragona P, Clayton JA, Ding J, Golebiowski B, et al. Sex, Gender, and Hormones Report. Ocul Surf. 2017;15(3):284-333. DOI: 10.1016/j.jtos.2017.04.0018.

9. Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3):334-65. DOI: 10.1016/j.jtos.2017.05.0039.

10. Theander E, Jacobsson LTH. Relationship of Sjögren's syndrome to other connective tissue and autoimmune disorders. Rheum Dis Clin North Am. 2008;34(4):935-47. DOI: 10.1016/j.rdc.2008.08.00910.

11. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. Ocular Surface. 2017;15(3):438-510. DOI: 10.1016/j.jtos.2017.05.01111.

12. Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: Report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Investigative Ophthalmology and Visual Science. 2011;52(4):1938-78. DOI: 10.1167/iovs.10-6997c12.

13. Gomes JA, Azar DT, Baudouin C, Efron N, Hirayama M, Horwath-Winter J, et al. TFOS DEWS II iatrogenic report. Ocular Surface. 2017;15(3):511-38. DOI: 10.1016/j.jtos.2017.05.00413.

14. Cohen E, Spierer O. Dry Eye Post-Laser-Assisted In Situ Keratomileusis: Major Review and Latest Updates. J Ophthalmol. 2018;2018:4903831. DOI: 10.1155/2018/490383114.

15. Baudouin C, Messmer E, Aragona P, Geerling G, Akova YA, Benítez-del-Castillo J, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100(3):300-6. DOI: 10.1136/bjophthalmol-2015-30741515.

16. Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II Diagnostic Methodology report. Ocular Surface. 2017;15(3):539-74. DOI: 10.1016/j.jtos.2017.05.00116.

17. Baudouin C, Aragona P, Van Setten G, Rolando M, Irkeç M, Del Castillo JB, et al. Diagnosing the severity of dry eye: A clear and practical algorithm. British Journal of Ophthalmology. 2014;98(9):1168-76. DOI: 10.1136/bjophthalmol-2013-30461917.

18. Yokoi N, Georgiev GA. Tear-film-oriented diagnosis for dry eye. Japanese Journal of Ophthalmology. 2019;63(2):127-36. DOI: 10.1007/s10384-018-00645-418.

19. Markoulli M, Hui A. Emerging targets of inflammation and tear secretion in dry eye disease. Drug Discovery Today. 2019;24(8):1427-32. DOI: 10.1016/j.drudis.2019.02.00619.

20. Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II Management and Therapy report. Ocul Surf. 2017;15(3):575-628. DOI: 10.1016/j.jtos.2017.05.00620.

21. de Paiva CS, Pflugfelder SC, Ng SM, Akpek EK. Topical cyclosporine A therapy for dry eye syndrome. Cochrane Database Syst Rev. 2019;9(9):CD010051. DOI: 10.1002/1465185821.

22. de Oliveira RC, Wilson SE. Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease. Clinical Ophthalmology. 2019;13:1115-22. DOI: 10.2147/OPTH.S18441222.

23. Rojas I, Estrada BV. Queratoconjuntivitis seca. En: Rio M, Fernández L, Hernández JR, Ramos M. Oftalmología. Diagnóstico y tratamiento. 2nd. ed. La Habana: Ecimed; 2018. p. 50-4.